Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical anti-infectives developer Anadys Pharmaceuticals has initiated a UK phase I clinical trial of its oral hepatitis treatment candidate, ANA975, in healthy volunteers.
Subscribe to our email newsletter
ANA975 is an oral prodrug of Anadys’ proprietary small molecule compound isatoribine, an agonist of toll-like receptor 7 (TLR7). Results from clinical trials of isatoribine have demonstrated a statistically significant viral load reduction in hepatitis C patients by activating innate immunity.
The phase I clinical trial, which introduces ANA975 to the clinic ahead of schedule, is designed to evaluate the safety, tolerability and pharmacokinetics of ANA975 in healthy volunteers. The study is an open-label, ascending single-dose evaluation and is being conducted in the UK.
“We expect that ANA975 will provide the same combination of anti-viral effect and tolerability as observed with isatoribine, but with the added advantage of oral administration,” said Dr Steve Worland, Anadys’ executive vice president of R&D.
“The pharmaceutical properties of ANA975 along with the preclinical data further support our belief that ANA975 provides the potential to become an orally administered frontline treatment for chronic hepatitis C virus (HCV) infection,” he concluded.